PEAR实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (19 Apr 2023 @ 04:00):

Stats
今日成交量	66.30M
平均成交量	10.09M
市值	4.09M
EPS	$0 ( 2024-03-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0811
ATR14	$0.0310 (645.83%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-10	5am Partners Iv, Llc	Sell	3 172 769	Class A Common Stock
2023-04-10	5am Partners Iv, Llc	Sell	534 855	Class A Common Stock
2023-02-15	Snow Ellen	Buy	199 864	Restricted Stock Units
2023-02-16	Snow Ellen	Buy	40 000	Restricted Stock Units
2023-02-15	Brenner Erin K.	Buy	952 380	Restricted Stock Units

INSIDER POWER
29.92
Last 97 transactions
Buy: 13 156 765 \| Sell: 6 479 057

音量相关性

長: -0.32 (neutral)

短: -0.74 (moderate negative)

Signal:(22.192) Neutral

Pear Therapeutics, Inc. 相关性

10 最正相关
VORB	0.976
BRQS	0.975
IRDM	0.974
PYR	0.972
APPS	0.97
PTE	0.97
AUPH	0.968
CYAN	0.967
TRIT	0.966
BHTG	0.966

10 最负相关
GXII	-0.982
SHLD	-0.98
CDRO	-0.977
ISEE	-0.977
CRTO	-0.975
NXGN	-0.973
TXRH	-0.973
ARYD	-0.97
APP	-0.97
ADSE	-0.969

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Pear Therapeutics, Inc. 相关性 - 货币/商品

-0.45
( neutral )

-0.84
( strong negative )

0.00
( neutral )

-0.29
( neutral )

0.38
( neutral )

0.80
( moderate )

Pear Therapeutics, Inc. 财务报表

Annual	2022
营收:	$12.69M
毛利润:	$4.51M (35.54 %)
EPS:	$-0.170

FY	2022
营收:	$12.69M
毛利润:	$4.51M (35.54 %)
EPS:	$-0.170

FY	2021
营收:	$4.21M
毛利润:	$-1.03M (-24.36 %)
EPS:	$-0.473

FY	2020
营收:	$9.38M
毛利润:	$7.67M (81.69 %)
EPS:	$-0.784

Financial Reports:

No articles found.

Pear Therapeutics, Inc.

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.